Información del artículo
:La somatostatina es un tetradecapéptido cíclico ampliamente distribuido en el organismo. La utilidad clínica de la somatostatina, y en especial de sus análogos de semivida prolongada, se centra en el diagnóstico y la terapéutica de dos procesos, los tumores endocrinos gastroenteropancreáticos, donde constituye un elemento central en el diagnóstico (gammagrafía con análogos de somatostatina), es de gran eficacia en el control de los síntomas en pacientes con tumores funcionales activos, y en los últimos años, gracias a su papel vehiculizador de partículas radiactivas, se ha convertido en un elemento importante en la terapia antineoplásica de estos tumores; por otro lado, es el tratamiento médico de elección en la acromegalia, y es útil en el tratamiento de los tumores hipofisarios no productores de hormona de crecimiento, en especial en los tirotropinomas.
Palabras clave:
Análogos de somatostatina
Tumores gastroenteropancreáticos
Tumores hipofisarios
:Somatostatin (SS) is a cyclic tetradecapeptide, widely distributed in the body. The clinical applications of somatostatin, and more importantly the long-acting analogues, are mainly for the diagnosis and treatment of two situations, namely gastroenteropancreatic endocrine tumors, where they constitute an important diagnostic tool (scintigraphy with somatostatin analogues), are highly efficient in the management of symptoms of patients with active tumors, and more recently has been advocated in the treatment of cancer, as a carrier of radioactive particles; somatostatin analogues are also the main medical treatment for acromegaly, and have proven utility in the treatment of non-GH producing tumors, especially thyrotropinomas.
Key words:
Somatostatin analogs
Gastroenteropancreatic tumors
Pituitary tumors
El Texto completo está disponible en PDF
Biblografía
[1.]
I. Shimon, S. Melmed.
Somatostatin receptors and analogues: history, actual trends and prospective, and future of medical therapy in secreting pituitary tumors.
II° Workshop neuroendocrinológico multidisciplinario “Aspectti chirurgici dei tumori ipofisari e cardiovascolari dell'acromegalia”, (1998),
[2.]
M.M. Albareda, S.M. Webb.
Acromegalia tratamiento médico.
Endocrinología, 45 (1998), pp. 156-162
[3.]
C. Beglinger, J. Drewe.
Somatostatin and octreotide: physiological background and pharmacological application.
Digestion, 60 (1999), pp. 2-8
[4.]
K. Öberg.
Advances in chemotherapy and biotherapy of endocrine tumors.
Curr Opin Oncol, 10 (1998), pp. 58-65
[5.]
H. Imam, B. Eriksson, E.T. Janson.
Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype antibodies.
Cancer Res, 58 (1998), pp. 2375
[6.]
N. Hukovic, R. Panetta, V. Kumar, Y. Patel.
Agonist-dependent regulation of cloned human somatostatin receptor type 1-5; subtype selective internalization or up-regulation.
Endocrinology, 68 (1996), pp. 844-850
[7.]
J.C. Gillis, S. Noble, K.L. Goa.
Octreotide long acting release (LAR): A review of its pharmacological properties and therapeutic use in the managment of acromegaly.
Drugs, 53 (1997), pp. 681-699
[8.]
L. Saltz, B. Trochanowski, M. Buckley, B. Heffernan, D. Niedzwiecki, Y. Tao, D. Kelsen.
Octreotide as antineoplastic agent in the treatment of functional and nonfunctional neuroendocrrine tumors.
Cancer, 72 (1993), pp. 244-248
[9.]
F. Tortosa, A. De Leiva.
Tratamiento médico de los tumores endocrinos gastroenteropancreáticos.
Endocrinología gastroenteropancreática. Barcelona, pp. 425-442
[10.]
M.H. Kulke, R.J. Mayer.
Carcinoid tumors.
N Engl J Med, 340 (1999), pp. 858-868
[11.]
E. Sugimoto, L. Lorelius, B. Erikson, K. Oberg.
Midgut carcinoid tumors: CT appearance.
Acta Radiol, 36 (1995), pp. 367-371
[12.]
P.K. Woodard, J.M. Feldman, S.S. Pane, M.E. Baker.
Midgut carcinoid tumors: CT findings and biochemical profiles.
J Comput Assist Tomogr, 19 (1995), pp. 400-405
[13.]
Koberg, B. Skogseid.
The ultimate biochemical diagnosis of endocrine pancreatic tumors in MEN-1.
J Intern Med, 243 (1998), pp. 471-476
[14.]
R.J. Pelley, R.M. Bukowski.
Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract.
Curr Opin Oncol, 9 (1997), pp. 68-74
[15.]
B. Eriksson, H. Arnberg, P.G. Lindgren, L.E. Lörelius.
Neuroendocrine pancreatic tumors: clinical presentation, biochemical and histopathological findings in 84 patients.
J Intern Med, 228 (1990), pp. 103-113
[16.]
J.A. Madura, O.W. Cummings, E.A. Wierke, T. Broadie, R. Goulet, T. Howard.
Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort.
Am Surg, 63 (1997), pp. 573-578
[17.]
H. Martensson, G. Böttcher, F. Sundler, A. Nobin.
Localization and peptide content of endocrine pancreatic tumors.
Ann Surg, 212 (1990), pp. 607-614
[18.]
J. Fedorak, T.C. Ko, D. Gordon, M. Flisak, R.A. Prinz.
Localization of islet cell tumors of the pancreas: A review of current techniques.
Surgery, 113 (1993), pp. 242-249
[19.]
C.M.P. King, R.H. Reznek, J.E. Dacie, JAH. Wass.
Review imaging islet cell tumors.
Clin Radiol, 49 (1994), pp. 295-303
[20.]
W.J. Schirmer, W.S. Melvin, R.M. Rush, T.M. O'Dosorio.
Indium-111-pentreotide scanning versus conventional imaging techniques for the localization of gastrinoma.
Surgery, 118 (1995), pp. 1105-1114
[21.]
F. Gibril, J.C. Reynols, J.L. Doppman.
Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas.
Ann Intern Med, 125 (1996), pp. 26-34
[22.]
U. Pape, R. Mohammad, W. Berger, H. Ropers, U. Plockinger, B. Wiedeman.
Multiple endocrine neoplasia type 1: a familial cancer syndrome and its genetic.
Oncol in Pract, 1 (1999), pp. 11-16
[23.]
R.F. Gagel.
Multiple endocrine neoplasia.
Williams textbook of endocrinology (9.a ed.), pp. 1627-1650
[24.]
L. Forga.
Tumores endocrinos digestivos. Libro de resumenes XIII curso de Endocrinologia para posgraduados de la SEEN.
Toledo, (1999), pp. 205-220
[25.]
R. Vassilopoulou-Sellin, J. Ajani.
Islet cell tumors of the pancreas.
Endocrinol Metab Clin North Am;, 23 (1994), pp. 53-65
[26.]
H. Lang, K.J. Oldhafer, A. Weimann.
Liver transplantation for metastais neuroendocrine tumors.
Ann Surg,, 225 (1997), pp. 347-354
[27.]
K. Oberg.
Neuroendocrine gastrointestinal tumors.
Oncol Pract, 1 (1999), pp. 3-7
[28.]
W.W. De Herder, A. Van der Lely, SWJ. Lamberts.
Somatostatin analogue treatment of neuroendocrine tumors.
Postgrad Med J, 72 (1996), pp. 403-408
[29.]
R.G. Marlink, J.J. Lokich, J.R. Robins.
Hepatic arterial embolization for metastatic hormone-secreting tumors.
Cancer, 65 (1990), pp. 2227-2232
[30.]
R. Arnold.
Therapeutic strategies in the management of endocrine GEP tumours.
Eur J Clin Invest, 20 (1990), pp. 82-90
[31.]
L. Degen, C. Beglinger.
The role of octreotide in the treatment of gastroenteropatic endocrine tumors.
Digestion, 60 (1999), pp. 9-14
[32.]
K. Oberg.
Traitement biologique des tumeurs neuroendocrines malignes.
Ann Endocrinol (Paris), 59 (1998), pp. 46-47
[33.]
E. Bajetta, C. Carnaghi, L. Ferrari, I. Spagnoli, R. Mazzaferro, R. Buzzoni.
The role of somatostatin analogues in the treatment of gastroenteropancreatic endocrine tumours.
Digestion, 57 (1996), pp. 72-76
[34.]
P. Ruszniewski.
Le lanreotide a liberation prolongee dans le traitement des tumeurs neuroendocrines.
Ann Endocrinol (Paris), 59 (1998), pp. 51-52
[35.]
P. Tomassetti, M. Migliori, L. Gullo.
Slow realase Lanreotide treatment in endocrine gastrointestinal tumors.
Am J Gastroenterol, 93 (1998), pp. 1468-1471
[36.]
A.N.M. Wymenga, B. Erikson, P.L. Salmela, M.B. Jacobsen, E.J. Van Custen, R.H. Fiasse, et al.
Efficacy and safety of prolonged-release Lanreotide in patients with gastrointestinal neuroendocrine tumours and hormonerelated symptoms.
J Clin Oncol, 17 (1999), pp. 1111-1117
[37.]
Seal LJ, Panahloo A, Bloom SR, Meeran K. Lanreotida (Somatuline) is effective in an octreotide resistant glucagonoma. IV European congress of Endocrinology 1998, Sevilla. Abstract Book; P2-233
[38.]
J.A. Vazquez, E. Ugarte, G. Villar, S. Gaztambide.
Efecto de un analogo de somatostatina de liberacion retardada en dos casos de gastrinoma con metastasis.
Endocrinologia, 44 (1997), pp. 59A
[39.]
M.A. Botana Lopez, J.M. De Matias, J.I. Vidal.
Insulinoma benigno tratado con Lanreotide.
Endocrinologia, 44 (1997), pp. 60A
[40.]
J. Krassowski.
Comment on long-acting lanreotide inducing clinical and biochemical remission of acromegaly caused by disseminated GHRH secreting carcinoid.
J Clin Endocrinol Metabol, 84 (1999), pp. 1761-1762
[41.]
B. Eriksson, K. Oberg.
Sumario de 15 anos de tratamiento de los tumores neuroendocrinos con analogos de la somatostatina y perspectivas futuras. Ann Oncol (ed.
esp.), 8 (1999), pp. 28-36
[42.]
The UPDATE. Octreoscan®. Volumen 4, n.° 2, junio de 1998
[43.]
I. Virgolini, I. Szilvasi, A. Kurtaran, P. Angelberger, M. Raderer, E. Havlik, et al.
Indium-111-DOTA-Lanreotide: Biodistribution, Safety and radiation absorbed dose in tumor patients.
J Nucl Med, 39 (1998), pp. 1928-1936
[44.]
M. Leimer.
Response to treatment with Yttrium 90-DOTA-Lanreotide of a patient with metastatic gastrinoma.
J Nucl Med, 39 (1998), pp. 2090-2094
[45.]
Y. Greenman, S. Melmed.
Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.
J Clin Endocrinol Metab, 79 (1994), pp. 724-729
[46.]
Y. Greenman, S. Melmed.
Somatostatin receptor subtype in pituitary tumors.
Oncogenesis and molecular biology of pituitary tumors. Frontiers Horm Res, pp. 99-107
[47.]
Y. Yamada, S.R. Post, K. Wang, H. Medical, S. Tager, G.I. Bell, et al.
Cloning and functional caracterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney.
Proc Natl Acad Sci USA, 89 (1992), pp. 251-255
[48.]
K. Yasuda, S. Rens-Domiano, C.D. Breder, S.F. Law, C.B. Saper, T. Reisine, et al.
Cloning of a novel somatostatin receptor SSTR3 that is coupled to adenylyl cyclase.
J Biol Chem, 267 (1992), pp. 20422-20428
[49.]
R. Panetta, C. Patel Y.
Expressions of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors.
Life Sci, 56 (1995), pp. 333-342
[50.]
M Miller G, M Alexander J, A Bikkal H, L. Katznelson, T Zervas N, A. Klibanski.
Somatostatin receptor subtype gene expression in pituitary adenomas.
J Clin Endocrinol Metab, 80 (1995), pp. 1386-1392
[51.]
C Reubi J, U Heitz P, M. Landolt A.
Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses.
J Clin Endocrinol Metab, 65 (1987), pp. 65-73
[52.]
J. Bertherat, T. Brue, A. Enjalbert, G. Gunz, R. Rasolonjanahary, A. Warnet, et al.
Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon ¡§in vivo¡¨ and ¡§in vitro¡¨ hormonal secretion.
J Clin Endocrinol Metab, 75 (1992), pp. 540-546
[53.]
G. Faglia, N. Bazzoni, A. Spada, M. Arosio, B. Ambrosi, F. Spinelli, et al.
In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin (123I-SDZ 204-090).
J Clin Endocrinol Metab, 73 (1991), pp. 850-856
[54.]
W.W. De Herder.
Lamberts SWJ. Is there a role for somatostatin and its analogs in Cushing's syndrome?.
Metabolism, 45 (1996), pp. 83-85
[55.]
N.J. Younger Woodhouse, S. Dagogo-Jack, R. Judzewitsch.
Acute and long-term effects of octreotide in patients with ACTH dependent Cushing's syndrome.
Am J Med, 95 (1993), pp. 305-308
[56.]
U. Plockinger, M. Bader, W. Hopfenmuller, W. Saeger, H.J. Quabbe.
Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone response to octreotide therapy and do not correlate with tumor histology.
Eur J Endocrinol, 136 (1997), pp. 369-376
[57.]
N. Gesundheit, P.A. Petrick, M. Nissim, P.A. Dahlberg, J.L. Doppman, C.H. Emerson, et al.
Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of nine patients.
Ann Intern Med, 111 (1989), pp. 827-835
[58.]
A. Warnet, A.G. Harris, E. Renard, D. Martin, A. James-Deidier, P. Chaumet-Riffaud.
A prospective multicenter trial of octreotide in 24 patients with visual defects caused by non functioning and gonadotrophin-secreting pituitary adenomas. French Multicenter Octreotide Study Group.
Neurosurgery, 41 (1997), pp. 786-797
[59.]
F. Broson-Chazot, C. Houzard, C. Ajzenberg, M. Nocaudie, M. Duet, O. Mundler, et al.
Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: Correlation with hormonal and visual responses to octreotide.
Clin Endocrinol (Oxf), 47 (1997), pp. 589-598
[60.]
R.C. Smallridge.
Thyrotropin-secreting pituitary tumors.
Endocrinol Metab Clin North Am, 16 (1987), pp. 765-792
[61.]
I.E. McCutcheon, B.D. Weintraub, E.H. Oldfield.
Surgical treatment of thyrotropin-secreting adenomas.
J Neurosurg, 73 (1990), pp. 674-683
[62.]
P. Beck-Peccoz, F. Brucker-Davis, L. Persani, R.C. Smallridge, B.D. Weintraub.
Thyrotropin-secreting pituitary tumors.
Endocr Rev, 17 (1996), pp. 610-638
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición
